Organisation paid for research Program year 2025 Source: CMS Open Payments

First Oc Dermatology Research Inc

Neither a doctor nor a teaching hospital

Research payments

$3,610,708

655 payments

Through program year 2025, First Oc Dermatology Research Inc is reported as receiving $3,610,708 in research payments, across 655 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,489,078 245
2024 Research $1,740,899 258
2023 Research $380,731 152

Breakdown

Who paid Research payments · program years 2023–2025
  1. Sanofi US Services Inc. $931,427 116 payments
  2. Janssen Research & Development, LLC $882,484 68 payments
  3. Pfizer Inc. $331,443 68 payments
  4. Incyte Corporation $316,877 112 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $307,296 16 payments
  6. Ucb SA $224,059 10 payments
  7. Galderma Laboratories, L.P. $158,109 21 payments
  8. GlaxoSmithKline, LLC. $108,893 33 payments
  9. Eli Lilly and Company $90,478 7 payments
  10. Acrotech Biopharma LLC $78,615 9 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $375,375 26 payments
  2. Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $324,842 24 payments
  3. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $306,423 24 payments
  4. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $238,398 16 payments
  5. A Phase 3 Multicenter Longterm Extension Study Investigating the Efficacy and Safety of Abrocitinib With Or Without Topical Medications Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis $139,667 30 payments
  6. A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis $135,210 9 payments
  7. A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis $127,012 7 payments
  8. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis $124,844 21 payments
  9. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $116,513 32 payments
  10. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $114,250 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record